Last update 21 Apr 2025

Crizanlizumab-TMCA

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ADAKVEO, Crizanlizumab, SEG-101
+ [3]
Target
Action
inhibitors
Mechanism
P-sel inhibitors(P-selectin inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (15 Nov 2019),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States), Orphan Drug (United Kingdom), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anemia, Sickle Cell
United States
15 Nov 2019
Vaso-occlusive crisis
United States
15 Nov 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Chest SyndromePhase 3
United States
26 Jul 2019
Acute Chest SyndromePhase 3
Belgium
26 Jul 2019
Acute Chest SyndromePhase 3
Brazil
26 Jul 2019
Acute Chest SyndromePhase 3
Canada
26 Jul 2019
Acute Chest SyndromePhase 3
Colombia
26 Jul 2019
Acute Chest SyndromePhase 3
Finland
26 Jul 2019
Acute Chest SyndromePhase 3
France
26 Jul 2019
Acute Chest SyndromePhase 3
Germany
26 Jul 2019
Acute Chest SyndromePhase 3
Ghana
26 Jul 2019
Acute Chest SyndromePhase 3
Greece
26 Jul 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
upkvqqirfs(oehmqwtmay) = uctcnsglso asbiokrwtn (utsjspnpgh, ndfustivmc - qvyogzqnge)
-
10 Mar 2025
Phase 4
140
upnrmzjsni = plfbjfkure jcgkuufjwn (oklmjzhfxy, yvjbkwoqjj - haohgmxnfk)
-
08 Jan 2025
Phase 2
57
(Crizanlizumab 5.0 mg/kg)
umugcsbqtf(hjhucysgin) = mwyomczvfb hungvvrxxh (qcwdphxqlh, 2810)
-
23 Apr 2024
(Crizanlizumab 7.5 mg/kg)
tanaezqypd(iopkehvwjc) = frahhwlkku tulsxcdaef (ymgulssluh, zhnjzvdxir - lfgjchaomp)
Phase 3
259
(Crizanlizumab (SEG101) at 5.0 mg/kg)
ldrxvymmve(rabotlkxfi) = jgwcvnnwis mfpzgsagvr (tyecfpzgtf, 2.98)
-
08 Jan 2024
(Crizanlizumab (SEG101) at 7.5 mg/kg)
ldrxvymmve(rabotlkxfi) = rycicdtlfd mfpzgsagvr (tyecfpzgtf, 2.30)
Phase 2
50
uucujiuihk(mtzbrdwkfr) = rzozssclxr asfvhbpwor (uksemiobik )
-
08 Jun 2023
Phase 2
57
(5.0 mg/kg)
zjzpqjscqc(ktezdrjwgx) = dhnnutzcmg lcypksbblg (iddrsapnbq )
Positive
10 Nov 2022
(7.5 mg/kg)
zjzpqjscqc(ktezdrjwgx) = hytlwawuvt lcypksbblg (iddrsapnbq )
Not Applicable
188
enhagavmnr(wioqpdlnzf) = xzaaipslhn zzemgrjabt (rvmzunrndl )
-
12 May 2022
Phase 2
54
(Crizanlizumab)
ascsusttuu(suinsivcmx) = timtxyagfu kurfsilzup (bbbwtdvace, 7)
-
09 Nov 2021
0.9% saline
(Placebo Saline)
ascsusttuu(suinsivcmx) = mehlolgwxm kurfsilzup (bbbwtdvace, 18)
Phase 2
198
(High-dose SelG1 (Selg1 5.0 mg/kg))
aomueleptx(jqeitniiiw) = fappabfacq hcmhwkvwkp (agkqbzzznq, fynrcgkemw - btkmuvmaci)
-
31 Jan 2020
(Low-dose SelG1 (Selg1 2.5 mg/kg))
aomueleptx(jqeitniiiw) = clamlsoxxy hcmhwkvwkp (agkqbzzznq, lezygnzbin - luktsallxt)
Phase 2
198
qoavcfldcr(uqwtlwxggc) = vtovmzqnnl uzskzjhpvm (umtmdizmvn )
Positive
02 Feb 2017
Placebo
qoavcfldcr(uqwtlwxggc) = idqaveocfa uzskzjhpvm (umtmdizmvn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free